|
|
Vaccine Detail
|
CDX-1307 Vaccine |
| Vaccine Information |
- Vaccine Name: CDX-1307 Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: human chorionic gonadotropin-beta (hCG-β) (NCT01094496; NCIT_C77858)
- Immunization Route: Other
- Description: CDX-1307 is a vaccine for bladder cancer designed to generate an immune response against a protein called human chorionic gonadotropin-beta (hCG-β). hCG-β is made by several types of cancers, including bladder cancer, and has been shown to be associated with shorter times to development of metastases and reduced survival in bladder cancer. Administering the CDX-1307 vaccine will cause the body's immune system to attack bladder cancer cells in order to kill them or otherwise keep them from spreading or coming back. (NCT01094496) The human monoclonal antibody (B11) directed against the mannose receptor and linked to the beta-subunit of human chorionic gonadotropin (hCG beta) with potential immunostimulating and antineoplastic activities. The monoclonal antibody moiety of human monoclonal antibody B11-hCG beta fusion protein CDX-1307 binds to mannose receptors on antigen presenting cells (APCs), including human dendritic cells (DCs) and macrophages. APCs present the processed hCG beta antigen on their cell surfaces, which may initiate an antibody-dependent cell-mediated cytotoxicity (ADCC) response against hCG beta-expressing tumor cells. (NCIT_C77858)
|
| Host Response |
|
|
| References |
NCIT_C77858: Human Monoclonal Antibody B11-hCG Beta Fusion Protein CDX-1307 [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C77858]
NCT01094496: A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study) [https://clinicaltrials.gov/study/NCT01094496]
|
|
